Circadian Responses to Chemo

After exposure to curcumin, rat cancer cell populations undergo a daily cycle of cell death.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

PEXELS, GRATISOGRAPHYLike tissues throughout the body, tumors may also keep time, and a few studies have suggested that responses to cancer therapies may be stronger at particular times during the day. Related to this idea of “chronotherapy,” scientists this week (April 20) presented unpublished data at the American Association for Cancer Research (AACR) meeting in Philadelphia showing that the effect of curcumin on rat glioblastoma cells cycles according to a circadian rhythm.

Curcumin, a component of the spice turmeric, is known to have anti-cancer properties, and researchers are testing it out as a potential therapeutic agent. Given that curcumin can activate a gene important to regulating the circadian clock, Ashapurna Sarma, a graduate student in Michael Geusz’s lab at Bowling Green State University, along with colleagues at the University of Findlay’s College of Pharmacy in Ohio, wanted to see whether the anti-tumor effects of curcumin display any circadian rhythms.

The team exposed rat glioblastoma cells to curcumin and filmed them for five days via time-lapse microscopy. The researchers then went back through the images and at five-minute intervals, manually counted the cancer cells. They found that “there’s a lot more apoptosis” in the treated cells compared to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies